Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Completed 3Unknown 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 7Tumor-Agnostic 4Thoracic 4Other solid neoplasm 3Breast 2Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Neoplasms 4Neoplasm Metastasis 1

Interventions

pembrolizumab 46Paclitaxel 46Gemcitabine 41Carboplatin 37Docetaxel 35Bevacizumab 27Cisplatin 25Irinotecan 22Nivolumab 20Fluorouracil 20Erlotinib Hydrochloride 18Pemetrexed 17Capecitabine 17Sorafenib 16Magnetic Resonance Spectroscopy 16Cetuximab 16Afatinib 16Leucovorin 15regorafenib 14olaparib 13Specimen Handling 13Oxaliplatin 13trametinib 12Biopsy 12130-nm albumin-bound paclitaxel 11eribulin 10atezolizumab 10epothilone B 9Radiotherapy 9Midazolam 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × apatinib × Tumor-Agnostic × Clear all
NCT03396211 2023-04-07

A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer

Elevar Therapeutics

Phase 1 Completed
30 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT02836171 2017-02-27

Effect of Itraconazole on the Pharmacokinetics of Apatinib

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
20 enrolled
Tumor-Agnostic

Neoplasms

NCT02836821 2017-02-27

Effect of Rifampicin on the Pharmacokinetics of Apatinib

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
20 enrolled
Tumor-Agnostic

Neoplasms

NCT00633490 2008-07-22

Study of Apatinib as an Inhibitor of Tumor Angiogenesis

Fudan University

Phase 1 Unknown
18 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡